MAPK1 and neoplasm: The potential therapeutic implication of this finding is highlighted in our in vivo antitumor efficacy studies, in which ERK targeting by a small molecule inhibitor significantly reduced tumor growth in both iPAD, a genetically engineered murine model, and ES2 xenograft mouse model.